tiprankstipranks
Sino Biopharmaceutical Ltd (HK:1177)
HKEX:1177

Sino Biopharmaceutical (1177) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1177 Analyst Ratings

Moderate Buy
1Ratings
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Sino
Biopharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1177 Stock 12 Months Forecast

Average Price Target

HK$4.62
▲(47.56% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is HK$4.62 with a high forecast of HK$4.60 and a low forecast of HK$4.60. The average price target represents a 47.56% change from the last price of HK$3.13.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","2":"HK$2","3":"HK$3","4":"HK$4","5":"HK$5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.60340487319753,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$4.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.61869405,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$4.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.60340487319753,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$4.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2,3,4,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Aug<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,2.9848772979382714,3.119754595876543,3.2546318938148144,3.389509191753086,3.5243864896913575,3.6592637876296292,3.7941410855679005,3.929018383506172,4.063895681444444,4.198772979382715,4.333650277320986,4.468527575259258,{"y":4.60340487319753,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,2.9860533884615386,3.122106776923077,3.2581601653846155,3.394213553846154,3.5302669423076924,3.666320330769231,3.8023737192307694,3.938427107692308,4.074480496153846,4.210533884615385,4.346587273076923,4.482640661538461,{"y":4.61869405,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.85,2.9848772979382714,3.119754595876543,3.2546318938148144,3.389509191753086,3.5243864896913575,3.6592637876296292,3.7941410855679005,3.929018383506172,4.063895681444444,4.198772979382715,4.333650277320986,4.468527575259258,{"y":4.60340487319753,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.064,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.132,"date":1678406400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.054,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.152,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.693,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.394,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.355,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.958,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.35,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$4.60Average Price TargetHK$4.62Lowest Price TargetHK$4.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein
HK$3.00
Hold
-4.15%
Downside
Reiterated
11/02/23
Hold Rating for Sino Biopharmaceutical: Fair Valuation and Future Risks in Gx Drugs and Pipeline
Morgan Stanley
HK$4.80
Buy
53.35%
Upside
Reiterated
09/26/23
Sino Biopharmaceutical Ltd. (1177:HK) (SBMFF) PT Lowered to HK$4.80 at Morgan StanleyMorgan Stanley analyst Sean Wu lowered the price target on Sino Biopharmaceutical Ltd. (1177:HK) (OTC: SBMFF) to HK$4.80 (from HK$5.90) while maintaining a Overweight rating.
Deutsche Bank
HK$5.80
Buy
85.30%
Upside
Reiterated
08/28/23
We have adjusted our price target from HK$6.5 to HK$5.8, mainly to reflect our lower assumption for the Rmb exchange rate, based on 27x 2023E EPS. The target PER is based on 1 standard deviation below the 3-year average rolling fwd PER. Maintain Buy. Provided for the exclusive use of on 2023-09-28T12:22+00:00. DO NOT Pharmaceuticals / Disclosures *Other information available upon request Disclosure checklist Company Ticker Recent price* 3.01 (HKD) 25 Aug 2023 14 *Prices are current as of the end of the previous trading session unless otherwise indicated and are sourced from local exchanges via Reuters, Bloomberg and other vendors .
Nomura
HK$6.63
Buy
111.82%
Upside
Reiterated
08/02/23
Sino Biopharmaceutical Ltd. (1177:HK) (SBMFF) PT Lowered to HK$6.63 at Nomura/InstinetNomura/Instinet analyst Jialin Zhang lowered the price target on Sino Biopharmaceutical Ltd. (1177:HK) (OTC: SBMFF) to HK$6.63 (from HK$7.43) while maintaining a Buy rating.

Best Analysts Covering Sino Biopharmaceutical

Which Analyst Should I Follow If I Want to Buy HK:1177 and Sell After:
1 Month
Success Rate
0/4 ratings generated profit
0%
Average Return
-7.45%
reiterated a buy rating 7 months ago
Copying Jialin Zhang's trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -7.45% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Success Rate
0/4 ratings generated profit
0%
Average Return
-12.97%
reiterated a buy rating 7 months ago
Copying Jialin Zhang's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -12.97% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Success Rate
0/4 ratings generated profit
0%
Average Return
-19.95%
reiterated a buy rating 7 months ago
Copying Jialin Zhang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.95% per trade.
2 Years
Success Rate
0/4 ratings generated profit
0%
Average Return
-26.40%
reiterated a buy rating 7 months ago
Copying Jialin Zhang's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -26.40% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1177 Analyst Recommendation Trends

Rating
Apr 23
Aug 23
Sep 23
Nov 23
Jan 24
Strong Buy
3
4
4
3
2
Buy
0
0
0
0
0
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
4
4
4
3
In the current month, 1177 has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1177 average Analyst price target in the past 3 months is HK$4.62.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

1177 Financial Forecast

1177 Earnings Forecast

Next quarter’s earnings estimate for 1177 is HK$0.09 with a range of HK$0.09 to HK$0.09. The previous quarter’s EPS was HK$0.09. 1177 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.71% of the time in the same period. In the last calendar year 1177 has Outperformed its overall industry.
Next quarter’s earnings estimate for 1177 is HK$0.09 with a range of HK$0.09 to HK$0.09. The previous quarter’s EPS was HK$0.09. 1177 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 49.71% of the time in the same period. In the last calendar year 1177 has Outperformed its overall industry.

1177 Sales Forecast

Next quarter’s sales forecast for 1177 is HK$16.71B with a range of HK$16.01B to HK$17.42B. The previous quarter’s sales results were HK$17.28B. 1177 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 56.86% of the time in the same period. In the last calendar year 1177 has Outperformed its overall industry.
Next quarter’s sales forecast for 1177 is HK$16.71B with a range of HK$16.01B to HK$17.42B. The previous quarter’s sales results were HK$17.28B. 1177 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 56.86% of the time in the same period. In the last calendar year 1177 has Outperformed its overall industry.

1177 Stock Forecast FAQ

What is HK:1177’s average 12-month price target, according to analysts?
Based on analyst ratings, Sino Biopharmaceutical Ltd’s 12-month average price target is HK$4.62.
    What is HK:1177’s upside potential, based on the analysts’ average price target?
    Sino Biopharmaceutical Ltd has 47.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sino Biopharmaceutical Ltd a Buy, Sell or Hold?
          Sino Biopharmaceutical Ltd has a conensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Sino Biopharmaceutical Ltd’s share price target?
            The average share price target for Sino Biopharmaceutical Ltd is HK$4.62. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$4.60 ,and the lowest forecast is HK$4.60. The average share price target represents 47.56% Increase from the current price of HK$3.13.
              What do analysts say about Sino Biopharmaceutical Ltd?
              Sino Biopharmaceutical Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Sino Biopharmaceutical Ltd?
                To buy shares of HK:1177, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis